The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); BeiGene; Biocon; Eisai; Lilly
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
 
Tarek Meniawy
Honoraria - AstraZeneca/MedImmune
Consulting or Advisory Role - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Brandon Beagle
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
ZheZhen Li
Employment - AstraZeneca; BeiGene
Stock and Other Ownership Interests - BeiGene
 
Song Mu
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
John Wu
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Crystal S. Denlinger
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Lilly; Merck; Taiho Pharmaceutical
Research Funding - Agios (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genmab (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merrimack (Inst); Sanofi (Inst); Zymeworks (Inst)
 
Wells A. Messersmith
Consulting or Advisory Role - Five Prime Therapeutics (Inst); Gilead Sciences (Inst); Purdue Pharma (Inst); Tanabe Research (Inst)
Research Funding - Aduro Biotech (Inst); Alexo Therapeutics (Inst); AstraZeneca (Inst); Beigene (Inst); D3 (Inst); Immunomedics (Inst); OncoMed (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)